查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1606888

FLT3 抑制剂市场：按类型、产品和应用划分 - 2025-2030 年全球预测

FLT3 Inhibitors Market by Type (FLT3-ITD (Internal Tandem Duplication), FLT3-TKD (Tyrosine Kinase Domain)), Product (Gilteritinib, Midostaurin, Quizartinib), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年FLT3抑制剂市值为4.7529亿美元，预计2024年将达到5.3437亿美元，复合年增长率为14.98%，到2030年将达到12.6315亿美元。

FLT3 抑制剂是一种标靶治疗，主要用于透过解决 FMS 样蛋白酪氨酸激酶3 (FLT3) 基因的突变来治疗急性骨髓性白血病(AML)。对 FLT3 抑制剂的需求源自于 AML 患者中 FLT3 突变的高盛行率，这种突变与不良预后相关。其应用涵盖临床和研究环境，促进个人化医疗方法并增进对白血病病理病理学的理解。最终用户包括专门从事骨髓恶性肿瘤的医院、诊所和研究机构。白血病盛行率上升、标靶治疗意识增强以及药物开发技术的进步对市场开拓产生了重大影响。最近的趋势包括开发提高疗效并减少副作用的下一代 FLT3 抑制剂，以及开发提高治疗效果的联合治疗。然而，新兴市场面临药物开发高成本、潜在副作用、细菌抗药性的出现以及严格的监管途径等限制。此外，新兴市场的可及性问题以及来自其他标标靶治疗疗法的竞争也带来了进一步的挑战。创新和研究可以集中在增强药物传输机制、探索 FLT3 讯号通路中的新标靶以及进行真实世界的临床试验以检验这些抑制剂的临床效用。有前景的业务成长领域包括投资先进的临床试验，以建立卓越的疗效并提高市场渗透率。也建议建立策略伙伴关係，以加速药品核准和新兴市场的业务扩张。了解癌症治疗的竞争格局和动态性质对于相关人员不断适应市场趋势并优先进行填补当前治疗空白的研究至关重要。

主要市场统计
基准年[2023] 47529万美元
预计年份 [2024] 5.3437 亿美元
预测年份 [2030] 1,263.15 百万美元
复合年增长率（%） 14.98%

市场动态：揭示快速发展的 FLT3 抑制剂市场的关键市场洞察

FLT3 抑制剂市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球急性骨髓性白血病患者的治疗需求不断增加
    • 政府对癌症研究和治疗的支持和投资
  • 市场限制因素
    • 治疗费用高，治疗程序复杂
  • 市场机会
    • 改善FLT3抑制剂的核准情况
    • 持续研发新产品开发
  • 市场挑战
    • 对 FLT3 抑制剂副作用的担忧

波特五力：驾驭 FLT3 抑制剂市场的策略工具

波特的五力框架是了解 FLT3 抑制剂市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 FLT3 抑制剂市场的外部影响

外部宏观环境因素在塑造 FLT3 抑制剂市场的业绩动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解FLT3抑制剂市场的竞争状况

对 FLT3 抑制剂市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵 FLT3 抑制剂市场供应商绩效评估

FPNV定位矩阵是评估FLT3抑制剂市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了 FLT3 抑制剂市场的成功之路

对于希望加强在全球市场的影响力的公司来说，FLT3 抑制剂市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地对急性骨髓性白血病患者的治疗需求正在增加。
      • 政府在癌症研究和治疗方面的支持努力和投资
    • 抑制因素
      • 治疗费用高、治疗程序复杂
    • 机会
      • FLT3抑制剂核准情况改善
      • 持续研发新产品开发
    • 任务
      • 对 FLT3 抑制剂副作用的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 FLT3 抑制剂市场：依类型

  • FLT3-ITD（内部串联复製）
  • FLT3-TKD（蛋白酪氨酸激酶结构域）

第 7 章 FLT3 抑制剂市场：副产品

  • Gilteritinib
  • 米多斯託林
  • 奎札替尼

第八章 FLT3抑制剂市场：依应用分类

  • 医院/诊所
  • 研究室

第九章 北美和南美FLT3抑制剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太FLT3抑制剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲FLT3抑制剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • 4SC AG
  • Actinium Pharmaceuticals, Inc.
  • AROG Pharmaceuticals, INC.
  • Astellas Pharma Inc.
  • Bayer AG
  • Biomea Fusion, Inc.
  • Daiichi Sankyo Company, Limited
  • Hanmi Pharm.Co., Ltd.
  • Mirati Therapeutics, Inc.
  • Nerviano Medical Sciences Srl
  • Novartis AG
  • Takeda Pharmaceuticals
  • The Menarini Group
Product Code: MRR-2E76C3E47FC9

The FLT3 Inhibitors Market was valued at USD 475.29 million in 2023, expected to reach USD 534.37 million in 2024, and is projected to grow at a CAGR of 14.98%, to USD 1,263.15 million by 2030.

FLT3 inhibitors are a class of targeted therapies used predominantly in the treatment of acute myeloid leukemia (AML) by addressing mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The necessity of FLT3 inhibitors arises from the high prevalence of FLT3 mutations in AML patients, which are associated with poor prognosis. Their application extends to both clinical and research settings, facilitating personalized medicine approaches and advancing understanding of leukemic pathophysiology. End-users include hospitals, clinics, and research institutions that focus on hematological malignancies. The market growth is significantly influenced by the rising incidences of leukemia, increasing awareness about targeted therapies, and ongoing advancements in drug development technologies. Recent opportunities are evident in the development of next-generation FLT3 inhibitors with improved efficacy and reduced side effects, as well as in the exploration of combination therapies that enhance treatment outcomes. Nonetheless, the market faces limitations such as the high cost of drug development, potential side effects, resistance development, and stringent regulatory pathways. Furthermore, accessibility issues in emerging markets and competition from other targeted therapies present additional challenges. Innovation and research can focus on enhancing drug delivery mechanisms, exploring novel targets within the FLT3 signaling pathway, and conducting real-world studies to validate the clinical utility of these inhibitors. A promising area for business growth includes investing in advanced clinical trials to establish superior efficacy profiles and increase market penetration. Strategic partnerships for quicker drug approvals and expansions in emerging markets are also recommended. Understanding the competitive landscape and the dynamic nature of oncology treatments makes it crucial for stakeholders to continuously adapt to market trends and prioritize research that bridges current therapeutic gaps.

KEY MARKET STATISTICS
Base Year [2023] USD 475.29 million
Estimated Year [2024] USD 534.37 million
Forecast Year [2030] USD 1,263.15 million
CAGR (%) 14.98%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving FLT3 Inhibitors Market

The FLT3 Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing need to treat acute myeloid leukemia patients worldwide
    • Supportive government initiatives and investments in cancer research and treatments
  • Market Restraints
    • High cost of treatment coupled with complex treatment procedure
  • Market Opportunities
    • Improving approval landscape for FLT3 inhibitors
    • Ongoing research and development for new product developments
  • Market Challenges
    • Concerns relating to side impacts of FLT3 inhibitors

Porter's Five Forces: A Strategic Tool for Navigating the FLT3 Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the FLT3 Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the FLT3 Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the FLT3 Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the FLT3 Inhibitors Market

A detailed market share analysis in the FLT3 Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the FLT3 Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the FLT3 Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the FLT3 Inhibitors Market

A strategic analysis of the FLT3 Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the FLT3 Inhibitors Market, highlighting leading vendors and their innovative profiles. These include 4SC AG, Actinium Pharmaceuticals, Inc., AROG Pharmaceuticals, INC., Astellas Pharma Inc., Bayer AG, Biomea Fusion, Inc., Daiichi Sankyo Company, Limited, Hanmi Pharm.Co., Ltd., Mirati Therapeutics, Inc., Nerviano Medical Sciences S.r.l, Novartis AG, Takeda Pharmaceuticals, and The Menarini Group.

Market Segmentation & Coverage

This research report categorizes the FLT3 Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across FLT3-ITD (Internal Tandem Duplication) and FLT3-TKD (Tyrosine Kinase Domain).
  • Based on Product, market is studied across Gilteritinib, Midostaurin, and Quizartinib.
  • Based on Application, market is studied across Hospitals & Clinics and Research Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing need to treat acute myeloid leukemia patients worldwide
      • 5.1.1.2. Supportive government initiatives and investments in cancer research and treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment coupled with complex treatment procedure
    • 5.1.3. Opportunities
      • 5.1.3.1. Improving approval landscape for FLT3 inhibitors
      • 5.1.3.2. Ongoing research and development for new product developments
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns relating to side impacts of FLT3 inhibitors
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. FLT3 Inhibitors Market, by Type

  • 6.1. Introduction
  • 6.2. FLT3-ITD (Internal Tandem Duplication)
  • 6.3. FLT3-TKD (Tyrosine Kinase Domain)

7. FLT3 Inhibitors Market, by Product

  • 7.1. Introduction
  • 7.2. Gilteritinib
  • 7.3. Midostaurin
  • 7.4. Quizartinib

8. FLT3 Inhibitors Market, by Application

  • 8.1. Introduction
  • 8.2. Hospitals & Clinics
  • 8.3. Research Laboratories

9. Americas FLT3 Inhibitors Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific FLT3 Inhibitors Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa FLT3 Inhibitors Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 4SC AG
  • 2. Actinium Pharmaceuticals, Inc.
  • 3. AROG Pharmaceuticals, INC.
  • 4. Astellas Pharma Inc.
  • 5. Bayer AG
  • 6. Biomea Fusion, Inc.
  • 7. Daiichi Sankyo Company, Limited
  • 8. Hanmi Pharm.Co., Ltd.
  • 9. Mirati Therapeutics, Inc.
  • 10. Nerviano Medical Sciences S.r.l
  • 11. Novartis AG
  • 12. Takeda Pharmaceuticals
  • 13. The Menarini Group

LIST OF FIGURES

  • FIGURE 1. FLT3 INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. FLT3 INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FLT3 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES FLT3 INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES FLT3 INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. FLT3 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. FLT3 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FLT3 INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FLT3 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FLT3 INHIBITORS MARKET DYNAMICS
  • TABLE 7. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY FLT3-ITD (INTERNAL TANDEM DUPLICATION), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY FLT3-TKD (TYROSINE KINASE DOMAIN), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY GILTERITINIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY MIDOSTAURIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY QUIZARTINIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FLT3 INHIBITORS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES FLT3 INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA FLT3 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM FLT3 INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM FLT3 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM FLT3 INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. FLT3 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. FLT3 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023